News

After positive phase 3 trial data for its treatment for the bleeding disorder von Willebrand disease, Baxalta Inc. is awaiting FDA approval for the drug.

Experts weigh in on what to expect as provisions of the Medicare Access and CHIP Reauthorization Act roll out.

Technology that passes the non-techie empowerment test can empower your employees. Passing the test requires answering "yes" to these two simple questions.

As the healthcare system undergoes rapid change, there are three important trends that managed care executives should keep an eye on.

Here are some innovative ways EHR vendors are working to expand interoperability for providers and payers

There are advocates who say Medicare needs to increase the type of coverage it provides for beneficiaries.

Diabetes costs $322 billion per year in the U.S. Help empower consumers for a healthier bottom line.

On the 50th anniversary of Medicare, a look at the program's past, present, and future.

We want to know what you think about the top challenges facing the industry. Please take our quick survey. You’ll be entered to win a $200 Visa gift card.

FDA has granted priority review to naloxone nasal spray (Indivior) for the treatment of opioid overdose. If approved, naloxone nasal spray is expected to be the first FDA-approved intranasal naloxone product indicated to treat opioid overdose in the United States.

There have been 8 high-profile FDA approvals in the last few weeks. Here is an overview.

Healthcare spending growth faster than recent trends.

As a healthcare executive, leading your organization through today’s rapidly changing business environment means tackling serious issues. Here's how to do it right.

On July 24, FDA approved Daklinza (daclatasvir) for use with sofosbuvir to treat hepatitis C virus (HCV) genotype 3 infections.

FDA has approved sonidegib (Odomzo, Novartis) for locally advanced basal cell carcinoma.

Misconceptions about antibiotic use persist and continue to be more prevalent among parents of Medicaid-insured children, according to a study published in Pediatrics.

FDA has approved ombitsavir, paritaprevir and ritonavir (Technivie, AbbVie) for the treatment of hepatitis C virus genotype 4 infections.

With FDA’s approval of Praluent (alirocumab) injection, the first in a new class of injectable cholesterol-lowering drugs called PCSK9 inhibitors, comes the need for a utilization management approach.

Texas Children's Hospital has worked hard to increase physician engagement, and the payoff has been huge.

The Medicare Access and CHIP Reauthorization Act will expand the availability of Medicare data. Here's how that could impact the industry.

Here are four reasons a clinical pharmacist should be part of care teams for chronically-ill, elderly, and at-risk patient populations.

A recent research paper recommends combining the various parts of Medicare as it now stands into plans that he calls "Unified Medicare" and "Unified Medicare +."

AbbVie on July 24 reported weaker-than-expected revenue for its most recent quarter, which some analysts say is due to increased competition for its anti-inflammatory drug, Humira.

For health plans, the recently announced Anthem-Cigna deal signals that the industry is responding to structural changes in healthcare that have been building over the past few years.

Anthem’s acquisition of Cigna is being called the first “merger of titans” by industry watchers. Here's what to know.

Building on decades of effort to advance diabetes care, HealthPartners of Minnesota, continues to refine its management strategies to meet the individual patient's needs.

FDA has granted CLIA waiver for the Alere i Strep A test. The test, which was cleared for marketing by FDA in April 2015, is the first molecular platform that detects Group A Streptococcus (GAS) bacteria in 8 minutes or less.

The current global Parkinson’s disease market is characterized by a number of unmet needs, which include addressing the motor complications of dyskinesia and off-episodes. The recent approval of novel therapies and reformulations of existing drugs has the potential to fulfill some of these unmet needs, particularly in patients with advanced disease.

FDA has granted CLIA waiver to Theranos for herpes simplex virus test and test system.

Patients with moderate to severe atopic dermatitis (AD)-or eczema-may be successfully treated using a rheumatoid arthritis (RA) drug recently shown to reverse 2 other skin conditions, vitiligo and alopecia areata, according to findings published early online in the Journal of the American Academy of Dermatology.